OncoDailyBreast (@OncoDailyBreast) header
OncoDailyBreast (@OncoDailyBreast) profile picture

OncoDaily Breast | Your source for the latest in breast cancer, clinical trials, immunotherapy, targeted treatments, and expert insights.

Joined March 2026
Photo by OncoDailyBreast (@OncoDailyBreast)Photo by OncoDailyBreast (@OncoDailyBreast)Photo by OncoDailyBreast (@OncoDailyBreast)Photo by OncoDailyBreast (@OncoDailyBreast)Photo by OncoDailyBreast (@OncoDailyBreast)Photo by OncoDailyBreast (@OncoDailyBreast)Photo by OncoDailyBreast (@OncoDailyBreast)Photo by OncoDailyBreast (@OncoDailyBreast)Photo by OncoDailyBreast (@OncoDailyBreast)Photo by OncoDailyBreast (@OncoDailyBreast)
OncoDailyBreast retweeted
Oncologists Discuss NATALEE Trial The six-year #NATALEE trial results presented at #ESMO2026 showed an overall survival benefit and sustained improvements in invasive disease-free survival with adjuvant ribociclib plus endocrine therapy in patients with HR+/HER2โˆ’ early breast cancer. oncodaily.com/science/nataleโ€ฆ @KefahMokbel @SuyogCancer @emadshash @Timothee_MD @DrBarbiOnc @HundalJasmin @Aydah_AlAwadhi @DrSGraff @dr_yakupergun @kazuki_nozawa @sara_soliman7 @stolaney1 @Dr_Oncologista @DrHBurstein
2
10
1
15
1,258
OncoDailyBreast retweeted
As we continue our special OncoDaily tradition - the ๐Ÿญ๐Ÿฌ๐Ÿฌ ๐—œ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น ๐—ช๐—ผ๐—บ๐—ฒ๐—ป ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† - Weโ€™re proud to introduce the second part of our 2026 list, highlighting the next 10 remarkable women who are making a lasting impact in oncology.๐Ÿ’ซ ๐Ÿช„Zita Oligui Nguema(@ZitaOligui) is the First Lady of Gabon and an increasingly prominent advocate for strengthening cancer care and womenโ€™s health in Central Africa. In 2026, she served as high patron of Gabonโ€™s International Colloquium on the Future of Cancer Care and Research, which brought national and international experts together around plans to develop an advanced oncology center of excellence and strengthen prevention, early diagnosis, treatment, research, and specialist training in the country. Through her broader health advocacy, including the continental #BuildingResilience initiative, she has positioned improved access to healthcare as a central part of her public work and supported efforts to build more sustainable cancer-care capacity in Gabon. Read the second part below. ๐Ÿ”—shorturl.at/ah9aZ #Oncology #OncoDaily100 #OncoDaily #Cancer #100InfluentialWomen #WomenInOncology
2
5
237
OncoDailyBreast retweeted
As we continue our special OncoDaily tradition - the ๐Ÿญ๐Ÿฌ๐Ÿฌ ๐—œ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น ๐—ช๐—ผ๐—บ๐—ฒ๐—ป ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† - Weโ€™re proud to introduce the second part of our 2026 list, highlighting the next 10 remarkable women who are making a lasting impact in oncology.๐Ÿ’ซ ๐Ÿช„ Aditi Hazra (@aditihazra), PhD, MPH, is a cancer epidemiologist and Assistant Professor of Medicine at Harvard Medical School(@harvardmed) and Associate Epidemiologist at Brigham and Women's Hospital (@BrighamWomens), with research spanning breast cancer, cancer prevention, genetics, and population health. Aditi Hazra also serves as a Co-Chair of the Global Health Catalysts Summit. She has developed a particular focus on inflammatory breast cancer, contributing to research on its molecular biology, treatment patterns, and disparities in care, including the international BRIDGES study involving clinicians across 36 low- and middle-income countries. Her broader work addresses inequities in cancer outcomes โ€“ from breast cancer among refugee populations to strengthening breast cancer research within the U.S. Veterans Health Administration โ€“ bringing an epidemiologic and global-health perspective to improving cancer prevention, detection, and care. Read the second part below. ๐Ÿ”—shorturl.at/ah9aZ #Oncology #OncoDaily100 #OncoDaily #Cancer #100InfluentialWomen #WomenInOncology
2
1
2
268
OncoDailyBreast retweeted
As we continue our special OncoDaily tradition - the ๐Ÿญ๐Ÿฌ๐Ÿฌ ๐—œ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น ๐—ช๐—ผ๐—บ๐—ฒ๐—ป ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† - Weโ€™re proud to introduce the second part of our 2026 list, highlighting the next 10 remarkable women who are making a lasting impact in oncology.๐Ÿ’ซ ๐Ÿช„Julie Kim is President and CEO of Takeda Pharmaceutical Company (@TakedaPharma), becoming in June 2026 the first woman and first Korean American to lead the 245-year-old company. With more than three decades of global healthcare leadership, she now oversees Takedaโ€™s worldwide strategy and pipeline, including its oncology portfolio spanning hematologic malignancies and solid tumors. Under her leadership, Takeda is advancing its late-stage oncology programs alongside its established medicines. Kim also serves on the PhRMA Board, extending her influence across pharmaceutical innovation, patient access, and global health policy. Read the second part below. ๐Ÿ”—shorturl.at/ah9aZ #Oncology #OncoDaily100 #OncoDaily #Cancer #100InfluentialWomen #WomenInOncology
2
2
358
OncoDailyBreast retweeted
As we continue our special OncoDaily tradition - the ๐Ÿญ๐Ÿฌ๐Ÿฌ ๐—œ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น ๐—ช๐—ผ๐—บ๐—ฒ๐—ป ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† - Weโ€™re proud to introduce the second part of our 2026 list, highlighting the next 10 remarkable women who are making a lasting impact in oncology.๐Ÿ’ซ ๐Ÿช„Suyapa Bejarano, MD, PhD, (@SuyapaSube) is a clinical oncologist and radiation oncologist who has spent decades expanding access to cancer care, prevention, and research in Honduras. Formerly Head of Oncology at Liga Contra el Cรกncer in San Pedro Sula, she founded PESCA, a volunteer initiative that brings cervical and other cancer screening directly to underserved rural communities; the program remained active in 2025. Her work with international collaborators has developed practical models for breast and cervical cancer screening, HPV testing, symptom management, and cancer research in resource-limited settings. She has also contributed to ASCO resource-stratified guidelines and, in 2026, co-authored a major prospective study examining breast cancer care and survival in Honduras. Read the second part below. ๐Ÿ”—shorturl.at/ah9aZ #Oncology #OncoDaily100 #OncoDaily #Cancer #100InfluentialWomen #WomenInOncology
2
3
288
OncoDailyBreast retweeted
As we continue our special OncoDaily tradition - the ๐Ÿญ๐Ÿฌ๐Ÿฌ ๐—œ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น ๐—ช๐—ผ๐—บ๐—ฒ๐—ป ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† - Weโ€™re proud to introduce the second part of our 2026 list, highlighting the next 10 remarkable women who are making a lasting impact in oncology.๐Ÿ’ซ ๐Ÿช„Sara Gore (@sara_gore) is an Emmy-winning television host, journalist, and breast cancer survivor known for her work on NBC's New York Live (@NBCNewYork) and Open House. After publicly sharing her breast cancer diagnosis in 2026, she used her platform to speak openly about the realities of diagnosis, treatment, and recovery. ๐ŸŽ—๏ธBy July, following surgery and treatment, Gore announced that she was currently cancer-free while continuing breast reconstruction and recovery. By sharing her diagnosis and recovery openly with a large public audience, she has brought visibility to the emotional realities of cancer, familial risk, and the importance of early detection, adding a deeply personal voice to breast cancer awareness. Read the second part below. ๐Ÿ”—shorturl.at/ah9aZ #Oncology #OncoDaily100 #OncoDaily #Cancer #100InfluentialWomen #WomenInOncology
2
3
215
OncoDailyBreast retweeted
As we continue our special OncoDaily tradition - the ๐Ÿญ๐Ÿฌ๐Ÿฌ ๐—œ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น ๐—ช๐—ผ๐—บ๐—ฒ๐—ป ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† - Weโ€™re proud to introduce the second part of our 2026 list, highlighting the next 10 remarkable women who are making a lasting impact in oncology.๐Ÿ’ซ ๐Ÿช„Barbara Jereczek-Fossa (@BarbaraJereczek), MD, PhD, is a radiation oncologist and President of the European Society for Radiotherapy and Oncology (@ESTRO_RT) for 2026โ€“2028. She is also Full Professor of Radiation Oncology at the University of Milan and Chair of the Department of Radiation Oncology at the European Institute of Oncology in Milan. Her research has advanced modern radiotherapy, particularly in prostate cancer, breast cancer, stereotactic radiotherapy, and treatment personalization, alongside extensive work in education and multidisciplinary cancer care. As an active member of European School of Oncology (@ESOncology) activities, she is helping shape the future of radiation oncology across Europe, with a focus on scientific innovation, collaboration, professional development, and global outreach. Read the second part below. ๐Ÿ”—shorturl.at/ah9aZ #Oncology #OncoDaily100 #OncoDaily #Cancer #100InfluentialWomen #WomenInOncology
2
2
271
OncoDailyBreast retweeted
As we continue our special OncoDaily tradition - the ๐Ÿญ๐Ÿฌ๐Ÿฌ ๐—œ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น ๐—ช๐—ผ๐—บ๐—ฒ๐—ป ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† - Weโ€™re proud to introduce the second part of our 2026 list, highlighting the next 10 remarkable women who are making a lasting impact in oncology.๐Ÿ’ซ ๐Ÿช„Sara Tolaney (@stolaney1), MD, MPH, FASCO is the Chief of the Division of Breast Oncology at DanaFarber -Farber Cancer Institute (@DanaFarber), where she also serves as Associate Director of the Susan F. Smith Center for Womenโ€™s Cancers. Her research has helped reshape breast cancer treatment through pivotal trials of antibodyโ€“drug conjugates and targeted therapies, including the DESTINY-Breast and ASCENT programs. In 2026, studies she helped lead supported the FDA approval of new first-line approach for metastatic triple-negative breast cancer and HER2-positive metastatic disease. Tolaney has been recognized with the AACR Outstanding Investigator Award for Breast Cancer Research, the FASCO distinction, and a 2026 Susan G. Komen Leadership Grant for her continued work advancing breast cancer therapeutics. Read the second part below. ๐Ÿ”—shorturl.at/ah9aZ #Oncology #OncoDaily100 #OncoDaily #Cancer #100InfluentialWomen #WomenInOncology
5
8
560
OncoDailyBreast retweeted
As we continue our special OncoDaily tradition - the ๐Ÿญ๐Ÿฌ๐Ÿฌ ๐—œ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น ๐—ช๐—ผ๐—บ๐—ฒ๐—ป ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† - Weโ€™re proud to introduce the second part of our 2026 list, highlighting the next 10 remarkable women who are making a lasting impact in oncology.๐Ÿ’ซ ๐Ÿช„ Isabel Mestres (@IsabelMestres) is the CEO of City Cancer Challenge (@CCan_org), where she leads efforts to strengthen cancer care systems and expand equitable access to quality cancer services in cities across low- and middle-income countries. With more than 18 years of experience in global health, public-private partnerships, and resource mobilization, she previously held senior leadership roles at C/Can and served as Director of Membership and Partnership Development at the Union for International Cancer Control (@uicc). In 2026, she is also leading โ€œThriving Cities, Healthy Women,โ€ an initiative spanning 15 cities to improve timely diagnosis and treatment for women with cancer, while continuing C/Canโ€™s work with ASCO to develop the next generation of women leaders in oncology. Read the second part below. ๐Ÿ”—shorturl.at/ah9aZ #Oncology #OncoDaily100 #OncoDaily #Cancer #100InfluentialWomen #WomenInOncology
2
1
204
OncoDailyBreast retweeted
As we continue our special OncoDaily tradition - the ๐Ÿญ๐Ÿฌ๐Ÿฌ ๐—œ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น ๐—ช๐—ผ๐—บ๐—ฒ๐—ป ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† - Weโ€™re proud to introduce the second part of our 2026 list, highlighting the next 10 remarkable women who are making a lasting impact in oncology.๐Ÿ’ซ ๐Ÿช„ Alli O'Neill, MD (@DrSolidTumors) is Clinical Director of the Solid Tumor Center and Director of Medical Therapies at the Liver Tumor Center at Dana-Farber/Boston Childrenโ€™s Cancer and Blood Disorders Center, as well as Associate Professor of Pediatrics at Harvard Medical School. She also serves as Vice President for Clinical Performance Management at Dana-Farber Cancer Institute(@DanaFarber). ๐Ÿ”Ž Her work focuses on rare pediatric solid tumors, particularly hepatoblastoma, hepatocellular carcinoma, and Ewing sarcoma, combining clinical care with translational research in imaging and targeted immunotherapy. She also chairs the Childrenโ€™s Oncology Group Liver Tumor Committee and works internationally through the Pediatric Hepatic International Tumor Trial and SIOP, helping shape research and treatment strategies for childhood liver cancers worldwide. Read the second part below. ๐Ÿ”—shorturl.at/ah9aZ #Oncology #OncoDaily100 #OncoDaily #Cancer #100InfluentialWomen #WomenInOncology
2
1
275
OncoDailyBreast retweeted
As we continue our special OncoDaily tradition - the ๐Ÿญ๐Ÿฌ๐Ÿฌ ๐—œ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น ๐—ช๐—ผ๐—บ๐—ฒ๐—ป ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† - Weโ€™re proud to introduce the second part of our 2026 list, highlighting the next 10 remarkable women who are making a lasting impact in oncology.๐Ÿ’ซ ๐Ÿช„Rachna Shroff MD, FASCO (@rachnatshroff) is a gastrointestinal oncologist. She is a Chief of Hematology and Oncology at the University of Arizona College of Medicine โ€“ Tucson and Associate Director of Clinical Investigations at the University of Arizona Comprehensive Cancer Center. She has led major clinical trials in cholangiocarcinoma, including the national SWOG S1815 study. ๐ŸŽ—๏ธ Shroff recently shared publicly that she is navigating a cancer diagnosis herself and, showing incredible devotion to her efforts for caring for people with cancer, she announced about launching a campaign to raise $1.35 million to permanently endow the ๐—–๐—ผ๐—ป๐—พ๐˜‚๐—ฒ๐—ฟ ๐—–๐—ฎ๐—ป๐—ฐ๐—ฒ๐—ฟโ€“๐—ฅ๐—ฎ๐—ฐ๐—ต๐—ป๐—ฎ ๐—ฆ๐—ต๐—ฟ๐—ผ๐—ณ๐—ณ ๐—ฌ๐—ผ๐˜‚๐—ป๐—ด ๐—œ๐—ป๐˜ƒ๐—ฒ๐˜€๐˜๐—ถ๐—ด๐—ฎ๐˜๐—ผ๐—ฟ ๐—”๐˜„๐—ฎ๐—ฟ๐—ฑ ๐—ถ๐—ป ๐—•๐—ถ๐—น๐—ถ๐—ฎ๐—ฟ๐˜† ๐—–๐—ฎ๐—ป๐—ฐ๐—ฒ๐—ฟ, ensuring sustained support for future generations of researchers in the fieldโ€”a cause inspired by the early-career award that helped launch her own research career. Read the second part below. ๐Ÿ”—shorturl.at/ah9aZ #Oncology #OncoDaily100 #OncoDaily #Cancer #100InfluentialWomen #WomenInOncology
5
1
11
9,951
OncoDailyBreast retweeted
We are proud to introduce the next 10 women featured in our 2026 list of ๐Ÿญ๐Ÿฌ๐Ÿฌ ๐—œ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น ๐—ช๐—ผ๐—บ๐—ฒ๐—ป ๐—ถ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† ๐Ÿฉท Since August 26, 2023, Womenโ€™s Equality Day in the United States has marked the beginning of a special OncoDaily tradition โ€“ the 100 Influential Women in Oncology. On this day, we launched an initiative to recognize 100 inspiring women making a difference in oncology around the world, highlighting 10 remarkable women each week. And this year, weโ€™re continuing the journey with our 2026 list of 100 Influential Women in Oncology, showcasing the remarkable efforts made by these inspiring women across the world to improve cancer care. โ–ช๏ธoncodaily.com/100/100-influeโ€ฆ Rachna Shroff (@rachnatshroff) Zita Oligui Nguema (@ZitaOligui) Isabel Mestres (@IsabelMestres) Sara Tolaney (@stolaney1) Barbara Jereczek-Fossa (@BarbaraJereczek Aditi Hazra (@aditihazra) Alli O'Neill (@DrSolidTumors) Sara Gore (@sara_gore) Suyapa Bejarano (@SuyapaSube) Julie Kim powered by The Boston Institute for Global Rankings (BIGR) ๐Ÿช #OncoDaily100 #Oncology #OncoDaily #cancer #100InfluentialWomen #WomenInOncology
3
8
2
30
8,910
OncoDailyBreast retweeted
๐ŸŽ—๏ธ Mammo 2026: Global Breast Cancer Virtual Congress Join internationally recognized breast oncology experts for two days of scientific exchange on the latest advances in breast cancer care. Topics will include ADCs, endocrine therapy, immunotherapy, precision diagnostics, surgical de-escalation, ctDNA, screening and more. Chaired by Giuseppe Curigliano (@curijoey), Antonio Marra (@antoniomarraMD), and Sara M. Tolaney (@stolaney1), Mammo 2026 will bring together oncology professionals from around the world to discuss evidence shaping clinical practice. ๐Ÿ“… October 8โ€“9, 2026 ๐ŸŒ FREE Virtual Congress ๐Ÿ‘‰ Register now: oncodaily.com/mammo-2026-gloโ€ฆ #Mammo2026
2
9
373
OncoDailyBreast retweeted
๐Ÿ”ด DAY 2 WE ARE LIVE ON X! The Community Oncology Global Congress 2026 continues today! ๐ŸŒ๐ŸŽ—๏ธ Join oncology experts and the global cancer community for live discussions, expert insights, and conversations focused on access, innovation, and the future of cancer care. ๐Ÿ“… August 28โ€“30, 2026 ๐ŸŒ Global Virtual Congress ๐Ÿ‘‰ Join us live now! oncodaily.com/project/communโ€ฆ #OncoDaily #CommunityOncology #Oncology #GlobalCongress
3
3
307
OncoDailyBreast retweeted
Todayโ€™s Sharsheret Webinar Will Highlight the Research Presented at ASCO Annual Meeting - Amy Comander @DrAmyComander oncodaily.com/voices/amy-comโ€ฆ
3
6
344
OncoDailyBreast retweeted
Can Mammograms Serve as an Opportunity for Lung Cancer Screening? - Kim Sandler
1
3
9
245
OncoDailyBreast retweeted
Anthracyclines are a type of adjuvant chemotherapy used to treat some breast cancers. These anti-tumor antibiotics work by stopping cancer cells from replicating or growing. If youโ€™ve been diagnosed with early-stage, HER2-negative breast cancer or metastatic breast cancer, your doctor may recommend an anthracycline as part of your treatment plan. Hereโ€™s what to know about how anthracyclines work and what to expect: bit.ly/3T4rfgU #BreastCancer #BreastCancerTreatment #Chemotherapy #BreastCancerWarriors
2
8
335
OncoDailyBreast retweeted
ICYMI - HPV vaccination linked to drastic reduction in cervical cancer deaths for young women in England, finds observational study in The Lancet. Explore the research: spkl.io/60187GJIQ
3
31
3
98
13,530
OncoDailyBreast retweeted
vigilantfox.com/p/what-happeโ€ฆ This reminds me of my late mother who was diagnosed with breast cancer in the late 1940s and told then to avoid the sun to prevent a recurrence.She did so the rest of her life but died of... cancer in the end anyways.
1
1
36
IVERMECTIN AND FENBENDAZOL END CANCER ๐ŸŽฏCONFIRMED: Epidemiologist Nicolas Hulscher states that complete remissions of stage IV cancers using antiparasitic drugs are already documented in peer-reviewed scientific literature. According to him, hundreds of studies show that ivermectin and fenbendazole activate more than 12 different anticancer mechanisms and act against more than a dozen types of cancer. Among the most impactful works cited by Hulscher is a case report published in Case Reports in Oncology. There, three patients with metastatic stage IV cancer are described who achieved complete remission documented by imaging and tumor markers: ๐Ÿ“ŒAn 83-year-old woman with breast cancer that had metastasized to the liver, lungs, and bones. After treatment, the PET scan showed complete remission, and she has shown no recurrence in nearly three years. ๐Ÿ“ŒA 75-year-old man with metastatic bone prostate cancer. His PSA dropped to undetectable levels, and the metastases disappeared completely. ๐Ÿ“ŒA 63-year-old man with highly advanced BRAFV600+ melanoma. His circulating tumor DNA went from 123 to 0 in less than two months, with confirmed remission. Additionally, a recent systematic review analyzed 26 studies with 36 real patients treated with ivermectin. No serious adverse effects were reported, and clinical improvements were observed even in cases of leukemias and lymphomas, many of them while continuing to receive conventional chemotherapy. Alternative scientists explain that these drugs attack cancer in multiple ways: they destabilize microtubules, induce programmed apoptosis, block the mTOR pathway, cut off the glucose supply to tumor cells, inhibit the formation of new blood vessels, and eliminate cancer stem cells. All this with medications that cost pennies and have been used in humans and animals for decades. While conventional medicine invests billions in high-cost therapies, on social media thousands of patients are already sharing personal testimonials: tumors that shrink or disappear, markers that normalize, and surgeries that end up being canceled. The question sweeping the world is whether this represents the greatest medical suppression in history or the most important discovery of the 21st century. The dissenting scientific community demands controlled clinical trials with urgency. For many terminal cancer patients, time has simply run out. What do you think? Give it an RT and share this information before it disappears, as it could save many lives. Your friends or family fighting cancer need to read this today.
25
298
8
762
25,903